Samsung Biologics has broken ground on Plant 4, a bio-manufacturing facility dubbed as ‘Super Plant’, in Incheon, South Korea.
The 238,000m2 multi-story building, which when constructed will be the world’s largest biopharmaceutical facility with a total manufacturing capacity of 256,000 lt, claimed the company.
Go deeper with GlobalData
Following the completion of Plant 4, Samsung Biologics is expected to be accountable for one-third of the total world’s bio CMO manufacturing capacity, providing a total of 620,000 litres from a single site.
Featuring a modular design, Plant 4 is expected to allow flexibility for some parts of the plant to commence manufacturing activities by the end of 2022.
The aim of the firm is to start full operations by 2023.
See Also:
Samsung Biologics claimed that to ensure client confidentiality and security, equipment and instruments will be completely implemented with data integrity and cybersecurity to cut down risk and provide real-time, secure access to information to clients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPlant 4 is being designed to scale to the varying needs of clients from large-scale commercial manufacturing to small-scale CMO.
The plant will feature a diverse line-up of bioreactors ranging from 2,000-liters, 10,000-liters, and 15,000-liters.
To provide a complete one-stop service, the plant will provide a full range of CDO, CMO, and CRO processes. This will include early-stage development capabilities and large-scale commercial manufacturing with integrated aseptic fill/finish capabilities and a full QC Lab for testing services.
Samsung Biologics CEO Dr Tae Han Kim said, “We are committed to bringing client satisfaction to the next level. Plant 4 will add unbeatable value to our capabilities to develop and manufacture bio-medicines with the highest quality and innovative technology. We will continue to invest, create jobs, and serve our valued clients as CMO, CDO, and CRO Champion in making life-saving drugs more accessible for all.”
Samsung Biologics intends to unveil a dedicated Plant 4 virtual showroom online in December. to provide detailed information and ongoing construction updates of the new facility.
——————————————————————————————————————–
Samsung Biologics begins construction of bio-manufacturing facility, known as ‘Super Plant’. (Credit: PR Newswire Association LLC.)
